Mirum Pharmaceuticals (MIRM) to Release Earnings on Wednesday

Mirum Pharmaceuticals (NASDAQ:MIRM) will issue its quarterly earnings data after the market closes on Wednesday, May 8th. Analysts expect the company to announce earnings of ($0.37) per share for the quarter. Parties that are interested in registering for the company’s conference call can do so using this link.

Mirum Pharmaceuticals (NASDAQ:MIRM) last released its quarterly earnings data on Wednesday, February 28th. The company reported ($0.66) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.34) by ($0.32). Mirum Pharmaceuticals had a negative net margin of 86.33% and a negative return on equity of 66.24%. The company had revenue of $69.55 million for the quarter, compared to analyst estimates of $66.73 million. On average, analysts expect Mirum Pharmaceuticals to post $-1 EPS for the current fiscal year and $1 EPS for the next fiscal year.

Mirum Pharmaceuticals Price Performance

Shares of Mirum Pharmaceuticals stock traded down $0.44 during midday trading on Tuesday, hitting $25.95. 17,740 shares of the company were exchanged, compared to its average volume of 542,750. The firm has a 50 day simple moving average of $26.06 and a 200-day simple moving average of $28.17. The company has a debt-to-equity ratio of 1.23, a current ratio of 4.45 and a quick ratio of 4.19. Mirum Pharmaceuticals has a 52 week low of $23.14 and a 52 week high of $35.56.

Analyst Ratings Changes

Several equities research analysts have recently commented on the stock. SVB Leerink reduced their target price on shares of Mirum Pharmaceuticals from $44.00 to $43.00 and set an “outperform” rating on the stock in a research note on Monday, March 18th. HC Wainwright reaffirmed a “buy” rating and set a $58.00 price objective on shares of Mirum Pharmaceuticals in a research note on Tuesday, April 2nd. JMP Securities lifted their target price on shares of Mirum Pharmaceuticals from $69.00 to $72.00 and gave the company an “outperform” rating in a research note on Thursday, March 14th. Stifel Nicolaus started coverage on Mirum Pharmaceuticals in a research report on Wednesday, April 17th. They set a “buy” rating and a $48.00 price target on the stock. Finally, Cantor Fitzgerald reiterated an “overweight” rating and issued a $35.00 price objective on shares of Mirum Pharmaceuticals in a research report on Thursday, February 29th. Eight equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Buy” and an average price target of $51.70.

Insider Activity at Mirum Pharmaceuticals

In other news, COO Peter Radovich sold 4,303 shares of the business’s stock in a transaction dated Monday, March 25th. The stock was sold at an average price of $25.80, for a total value of $111,017.40. Following the sale, the chief operating officer now directly owns 29,013 shares in the company, valued at $748,535.40. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. In other news, COO Peter Radovich sold 4,303 shares of Mirum Pharmaceuticals stock in a transaction that occurred on Monday, March 25th. The shares were sold at an average price of $25.80, for a total value of $111,017.40. Following the sale, the chief operating officer now directly owns 29,013 shares in the company, valued at $748,535.40. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO Eric Bjerkholt bought 2,000 shares of Mirum Pharmaceuticals stock in a transaction that occurred on Wednesday, March 27th. The shares were acquired at an average price of $24.80 per share, with a total value of $49,600.00. Following the acquisition, the chief financial officer now directly owns 14,000 shares of the company’s stock, valued at approximately $347,200. The disclosure for this purchase can be found here. 22.87% of the stock is currently owned by insiders.

Mirum Pharmaceuticals Company Profile

Mirum Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally.